GSK and Cambridge University Join Forces with £50 Million Investment to Tackle Kidney and Respiratory Diseases Using AI

GSK and Cambridge University Join Forces with £50 Million Investment to Tackle Kidney and Respiratory Diseases Using AI

(IN BRIEF) GSK and the University of Cambridge have announced a £50 million, five-year collaboration called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC) to accelerate research and development in kidney and respiratory diseases. The initiative combines GSK’s expertise in immunology and AI with Cambridge’s scientific research capabilities. It aims to improve disease understanding and develop more precise treatments for these conditions, which affect millions globally. The partnership will leverage AI and patient data to drive innovation in healthcare and improve patient outcomes.

(PRESS RELEASE) LONDON, 21-Oct-2024 — /EuropaWire/ — GSK and the University of Cambridge have announced a significant new five-year partnership, investing over £50 million into the Cambridge-GSK Translational Immunology Collaboration (CG-TIC). This initiative is designed to accelerate research and development in the fields of kidney and respiratory diseases by combining GSK’s expertise in immunology, AI, and clinical development with Cambridge’s world-class scientific knowledge. The collaboration aims to improve the understanding of disease mechanisms, treatment responses, and the development of translational biomarkers, enabling faster, more targeted treatment options.

The CG-TIC will focus on two major disease areas: kidney and respiratory diseases. Chronic kidney disease affects approximately 850 million people globally, while respiratory diseases impact around 545 million. The goal is to find more precise treatments for these conditions and advance therapeutic development. By leveraging AI and machine learning, researchers will analyze patient data to uncover insights that will drive future innovations in healthcare.

Tony Wood, GSK’s Chief Scientific Officer, emphasized the importance of collaboration in driving scientific progress: “We are excited to deepen our partnership with the University of Cambridge to harness the power of AI and our understanding of the immune system to help patients with complex diseases.”

Cambridge’s unique environment, including its Biomedical Campus and close ties with Cambridge University Hospitals, makes it an ideal location for this project. Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, highlighted that the collaboration will not only improve healthcare but also stimulate economic growth in the UK.

The collaboration will be jointly led by Nicolas Wisniacki, GSK’s VP of Clinical Research, and Professor David Thomas from the Cambridge Institute for Therapeutic Immunology and Infectious Diseases. This partnership demonstrates the UK’s leadership in life sciences, with Secretary of State for Science, Innovation, and Technology Peter Kyle noting the potential benefits for both national and global healthcare through innovative research and AI integration.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.

Media Contact:

Tim Foley
Vice President, Global Corporate Media Relations
corporate.media@gsk.com
+44 (0)20 8047 5502

SOURCE: GlaxoSmithKline plc